Skip to main content
. Author manuscript; available in PMC: 2023 Jan 28.
Published in final edited form as: Haemophilia. 2019 Jul;25(4):581–589. doi: 10.1111/hae.13717

FIGURE 2.

FIGURE 2

Master Protocol. All individuals with severe haemophilia A (HA) born in the United States are enrolled and screened for inhibitor formation at a uniform prespecified frequency. The inhibitor rate is compared between those who agree to enroll in the Inhibitor Prevention Trial, and those who agree to be followed only, thereby serving as concurrent controls and providing natural history data for inhibitor formation. Participants who develop inhibitors (HA-I), whether in the Enroll or Follow Groups may be screened to enroll in the Inhibitor Eradication Trial